Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation
Clinical trial NCT01531673 · COMPLETED
Trial details
- NCT number
- NCT01531673
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-02-01
- Primary completion
- 2014-03-01
- Enrollment
- 194
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.